Clinical Trial Update: Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab [Phase 3]

View source ↗

Summary

Open-label extension study assessing safety and efficacy of evolocumab in hypercholesterolemia completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Amgen | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2019-03-19